Cerebrovascular dysfunction can contribute to the pathophysiology of Alzheimer's disease (AD) and trigger angiogenesis. To date, no prior systematic review and meta-analysis (SRMA) study has attempted to qualitatively and quantitatively review existing literature examining angiogenic factors in AD.
Objective
In this review, we aimed to identify markers of angiogenesis in biofluids that can differentiate between individuals with AD and healthy older adults, and inform the role of angiogenesis in AD.
Methods
Using Medline (1946 to August 4, 2021), the literature was systematically searched for articles according to PRISMA guidelines. Angiogenesis and AD terms were searched as keywords and mapped to MeSH headings. A total of 18 studies (including 28 dependent effect sizes) were included in the meta-analysis. Hedges’ g was selected as the effect size of interest.
Results
A random-effects model including all eligible biofluid studies revealed a small and nonsignificant overall effect size (combined Hedges’ g = -0.26, 95% CI [-1.45, 0.92], p = 0.647), with significant heterogeneity (I2 = 98.6%, p < 0.0001). Moderator analysis revealed no significant difference based on which specific angiogenic biomarker was examined (i.e., vascular endothelial growth factor (VEGF) versus others).
Conclusions
VEGF-related marker levels were not significantly different in AD and normal aging. Based on our findings, few studies have examined fibroblast growth factor and platelet-derived growth factor-related markers; however, we believe they warrant further investigation. Identifying novel angiogenic biomarkers could elucidate the role of vascular mechanisms in AD and reveal potential therapeutic targets.
AsaharaTMasudaHTakahashiT, et al.Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res1999; 85: 221–228.
11.
Pias-PeleteiroJPerez-MatoMLopez-AriasE, et al.Increased endothelial progenitor cell levels are associated with good outcome in intracerebral hemorrhage. Sci Rep2016; 6: 28724.
12.
SobrinoTHurtadoOMoroMÁ, et al.The increase of circulating endothelial progenitor cells after acute ischemic stroke is associated with good outcome. Stroke2007; 38: 2759–2764.
13.
GengJWangLQuM, et al.Endothelial progenitor cells transplantation attenuated blood-brain barrier damage after ischemia in diabetic mice via HIF-1α. Stem Cell Res Ther2017; 8: 163.
14.
KongZHongYZhuJ, et al.Endothelial progenitor cells improve functional recovery in focal cerebral ischemia of rat by promoting angiogenesis via VEGF. J Clin Neurosci2018; 55: 116–121.
15.
HayakawaKSeoJHMiyamotoN, et al.Brain angiogenesis after stroke. In: MehtaJLDhallaNS (eds) Biochemical basis and therapeutic implications of angiogenesis. Cham: Springer International Publishing, 2013, pp.473–494.
16.
IssaRKrupinskiJBujnyT, et al.Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke. Lab Invest1999; 79: 417–425.
17.
CallahanCMApostolovaLGGaoS, et al.Novel markers of angiogenesis in the setting of cognitive impairment and dementia. J Alzheimers Dis2020; 75: 959–969.
18.
HohmanTJBellSPJeffersonAL. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline. JAMA Neurol2015; 72: 520.
19.
FerraraNGerberH-PLeCouterJ. The biology of VEGF and its receptors. Nat Med2003; 9: 669–676.
20.
MahoneyERDumitrescuLMooreAM, et al.Brain expression of the vascular endothelial growth factor gene family in cognitive aging and Alzheimer’s disease. Mol Psychiatry2021; 26: 888–896.
21.
VagnucciAHLiWW. Alzheimer’s disease and angiogenesis. Lancet2003; 361: 605–608.
22.
KapoorANationDA. Role of Notch signaling in neurovascular aging and Alzheimer’s disease. Semin Cell Dev Biol2021; 116: 90–97.
23.
SmythLCDHighetBJanssonD, et al.Characterisation of PDGF-BB:PDGFRβ signalling pathways in human brain pericytes: evidence of disruption in Alzheimer’s disease. Commun Biol2022; 5: 235.
24.
StopaEGGonzalezA-MChorskyR, et al.Basic fibroblast growth factor in Alzheimer’s disease. Biochem Biophys Res Commun1990; 171: 690–696.
25.
PalmerJCBarkerRKehoePG, et al.Endothelin-1 is elevated in Alzheimer’s disease and upregulated by amyloid-β. J Alzheimers Dis2012; 29: 853–861.
26.
FerraraNKerbelRS. Angiogenesis as a therapeutic target. Nature2005; 438: 967–974.
27.
Parsons-WingerterPElliottKEClarkJI, et al.Fibroblast growth factor-2 selectively stimulates angiogenesis of small vessels in arterial tree. Arterioscler Thromb Vasc Biol2000; 20: 1250–1256.
28.
LevinER. Endothelins. N Engl J Med1995; 333: 356–363.
29.
AsbyDBocheDAllanS, et al.Systemic infection exacerbates cerebrovascular dysfunction in Alzheimer’s disease. Brain2021; 144: 1869–1883.
30.
RyuJKChoTChoiHB, et al.Microglial VEGF receptor response is an integral chemotactic component in Alzheimer’s disease pathology. J Neurosci2009; 29: 3–13.
31.
FandosNPérez-GrijalbaVPesiniP, et al.Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst)2017; 8: 179–187.
32.
LeeJCKimSJHongS, et al.Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers. Exp Mol Med2019; 51: 1–10.
33.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med2021; 18: e1003583.
34.
BjörkqvistMOhlssonMMinthonL, et al.Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer’s disease. PLoS One2012; 7: e29868.
35.
BlaskoILedererWOberbauerH, et al.Measurement of thirteen biological markers in CSF of patients with Alzheimer’s disease and other dementias. Dement Geriatr Cogn Disord2006; 21: 9–15.
36.
BrosseronFTraschützAWidmannCN, et al.Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease. Alzheimers Res Ther2018; 10: 25.
37.
ChoS-JParkMHHanC, et al.VEGFR2 Alteration in Alzheimer’s disease. Sci Rep2017; 7: 17713.
38.
ChoS-JYunS-MJoC, et al.Altered expression of Notch1 in Alzheimer’s disease. PLoS One2019; 14: e0224941.
39.
CorsiMMLicastroFPorcelliniE, et al.Reduced plasma levels of P-selectin and L-selectin in a pilot study from Alzheimer disease: relationship with neuro-degeneration. Biogerontology2011; 12: 451–454.
40.
D’AnnaLAbu-RumeilehSFabrisM, et al.Serum interleukin-10 levels correlate with cerebrospinal fluid amyloid beta deposition in Alzheimer disease patients. Neurodegener Dis2017; 17: 227–234.
41.
GuoL-HAlexopoulosPPerneczkyR. Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci2013; 263: 553–560.
42.
HuangLJiaJLiuR. Decreased serum levels of the angiogenic factors VEGF and TGF-β1 in Alzheimer’s disease and amnestic mild cognitive impairment. Neurosci Lett2013; 550: 60–63.
MashayekhiFHadaviMVaziriHR, et al.Increased acidic fibroblast growth factor concentrations in the serum and cerebrospinal fluid of patients with Alzheimer’s disease. J Clin Neurosci2010; 17: 357–359.
45.
MateoILlorcaJInfanteJ, et al.Low serum VEGF levels are associated with Alzheimer’s disease. Acta Neurol Scand2007; 116: 56–58.
46.
MinersJSKehoePGLoveS, et al.CSF Evidence of pericyte damage in Alzheimer’s disease is associated with markers of blood-brain barrier dysfunction and disease pathology. Alzheimers Res Ther2019; 11: 81.
47.
SalzaROudartJ-BRamontL, et al.Endostatin level in cerebrospinal fluid of patients with Alzheimer’s disease. J Alzheimers Dis2015; 44: 1253–1261.
48.
SchreitmüllerBLeyheTStranskyE, et al.Elevated angiopoietin-1 serum levels in patients with Alzheimer’s disease. Int J Alzheimers Dis2012; 2012: 324016.
49.
WangZZhouWZhouB, et al.Association of vascular endothelial growth factor levels in CSF and cerebral glucose metabolism across the Alzheimer’s disease spectrum. Neurosci Lett2018; 687: 276–279.
50.
SchipkeCGGünterOWeinertC, et al.Definition and quantification of six immune- and neuroregulatory serum proteins in healthy and demented elderly. Neurodegener Dis Manag2019; 9: 193–203.
51.
JantaratnotaiNSchwabCRyuJK, et al.Converging perturbed microvasculature and microglial clusters characterize Alzheimer disease brain. Curr Alzheimer Res2010; 7: 625–636.
52.
DeiningerMHFimmenBAThalDR, et al.Aberrant neuronal and paracellular deposition of endostatin in brains of patients with Alzheimer’s disease. J Neurosci2002; 22: 10621–10626.
YangS-PBaeD-GKangHJ, et al.Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer’s disease. Neurobiol Aging2004; 25: 283–290.
55.
TangHMaoXXieL, et al.Expression level of vascular endothelial growth factor in hippocampus is associated with cognitive impairment in patients with Alzheimer's disease. Neurobiol Aging2013; 34: 1412–1415.
56.
MinersJSSchulzILoveS. Differing associations between aβ accumulation, hypoperfusion, blood–brain barrier dysfunction and loss of PDGFRB pericyte marker in the precuneus and parietal white matter in Alzheimer’s disease. J Cereb Blood Flow Metab2018; 38: 103–115.
57.
CicognolaCMattsson-CarlgrenNvan WestenD, et al.Associations of CSF PDGFRβ with aging, blood-brain barrier damage, neuroinflammation, and Alzheimer disease pathologic changes. Neurology2023; 101: e30–e39.
58.
KapoorANationDA. Platelet-derived growth factor-BB and white matter hyperintensity burden in APOE4 carriers. Cereb Circ Cogn Behav2022; 3: 100131.
59.
SweeneyMDSagareAPPachicanoM, et al.A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid. Alzheimers Dement2020; 16: 821–830.
60.
VrillonAAshtonNJBouaziz-AmarE, et al.Dissection of blood–brain barrier dysfunction through CSF PDGFRβ and amyloid, tau, neuroinflammation, and synaptic CSF biomarkers in neurodegenerative disorders. eBioMedicine2025; 115: 105694.
61.
AlamRMradYHammoudH, et al.New insights into the role of fibroblast growth factors in Alzheimer’s disease. Mol Biol Rep2022; 49: 1413–1427.
62.
KaurAFouadMHPozzebonC, et al.Sex differences in the association between vascular risk factors and cognitive decline: a UK biobank study. JACC Adv2024; 3: 100930.
63.
MontagneANikolakopoulouAMHuuskonenMT, et al.APOE4 Accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimer’s mice via cyclophilin A independently of amyloid-β. Nat Aging2021; 1: 506–520.
64.
DobsonRPattersonKMalikR, et al.Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer’s disease. J Neurol Neurosurg Psychiatry2024; 95: 796–803.
65.
SinghCSBChoiKBMunroL, et al.Reversing pathology in a preclinical model of Alzheimer’s disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics. eBioMedicine2021; 71: 103503.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
